This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD 3100 plus G-CSF can successfully mobilize CD34+ cells from non Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma previously failing mobilization with chemotherapy and/or cytokine treatment. Bone Marrow Transplant 2008; 41: 330–338.
Devine S, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.
Wang TF, Wen SH, Chen RL, Lu CJ, Zheng YJ, Yang SH et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008; 14: 1305–1311.
Anderlini P, Przepiorka D, Seong C, Smith T, Huh Y, Lauppe J et al. Factors affecting mobilization of CD341 cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507–512.
Vasu S, Leitman SF, Tisdale JF, Hsieh M, Childs R, Barrett J et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092–2100.
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch D, Watt M . Peripheral blood stem cell yield in 400 normal donors mobilized with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517–525.
Richa E, Papari M, Allen J, Marinez G, WIckrema A, Anastasi J et al. Older age but not donor health impairs allogeneic granulocyte colony stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2009; 15: 1394–1399.
DiPersio JF, Micallef IN, Stiff PJ, Bolwell B, Maziarz R, Jacobsen E et al. Phase 3 prospective randomized double-blind placebo-controlled trial of plerixafor plus G-CSF versus placebo plus G-CSF for autologous stem cell mobilization and transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
Leotta S, Poidomani M, Maura E, Spadaro A, Marturano E, Milone G . AMD 3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor alter failed marrow harvest. Bone Marrow Transplant 2011; 46: 314–316.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JS is on the Speaker's Bureau for Genzyme that produces plerixafor. The authors declare no sources of support.
Rights and permissions
About this article
Cite this article
Schriber, J., Fauble, V., Sproat, L. et al. Plerixafor ‘just in time’ for stem cell mobilization in a normal donor. Bone Marrow Transplant 46, 1026–1027 (2011). https://doi.org/10.1038/bmt.2010.226
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.226